Earnings Call Insights: TG Therapeutics (TGTX) Q1 2025
Management View
- CEO Michael Weiss highlighted robust performance for Q1 2025, with BRIUMVI achieving US net sales of $119.7 million, reflecting a 16% sequential growth and 137% year-over-year growth. Weiss emphasized increasing adoption by healthcare providers and patient